Cislieva 50 mg Injection Exporter from India to USA, UK, Australia, and South Africa
At Ernest Oncology (a division of Ernest Pharmaceutical Pvt. Ltd.), we are an internationally recognized exporter, bulk supplier, and distributor of critical oncology formulations. We specialize in the secure, compliant, and efficient supply of Cislieva 50 mg Injection (Cisplatin Injection USP, 50 mg/50 mL) to healthcare providers, hospitals, and pharmaceutical distributors worldwide, with targeted delivery networks in the USA, UK, Australia, and South Africa.
1. Product Information: Cislieva 50 mg Injection
Cislieva 50 mg Injection contains Cisplatin, a transition metal complex and platinum-based antineoplastic agent. It is a cornerstone medication utilized in the management of various solid tumors.
Key Product Details
Composition: Cisplatin USP 50 mg / 50 mL (1 mg/mL solution for injection).
Therapeutic Class: Alkylating agent / Platinum coordination complex.
Formulation Type: Sterile solution for intravenous (IV) infusion.
Storage Temperature: Store between 15°C and 25°C. Protect from light. Do not freeze.
2. Mechanism of Action
Cislieva functions as an alkylating agent that interferes directly with the genetic material of malignant cells:
DNA Cross-linking: The active compound penetrates the cell membrane, aquates, and binds to DNA strands to form inter-strand and intra-strand cross-links.
Inhibition of Synthesis: This binding interrupts the spatial structure and base-pairing of DNA, blocking both replication and transcription processes.
Apoptosis: The unrepairable genetic damage triggers programmed cell death (apoptosis) in rapidly dividing cancerous tissue.
3. Therapeutic Indications and Uses
Cislieva 50 mg Injection is indicated for:
Testicular Cancer: Used as a first-line agent for metastatic and advanced testicular tumors.
Ovarian Cancer: Advanced epithelial ovarian carcinoma, typically in combination with other alkylating or taxane agents.
Bladder Cancer: Advanced transitional cell bladder cancer.
Other Solid Tumors: Squamous cell carcinoma of the head and neck, cervical cancer, small cell and non-small cell lung cancer, and esophageal cancer.
4. Administration and Safety Warnings
Administration
Route of Administration: Administered exclusively via Intravenous (IV) infusion.
It is diluted in appropriate solutions (such as Sodium Chloride or Dextrose) and administered slowly under clinical supervision. Pre- and Post-Hydration: Cisplatin therapy requires intensive intravenous hydration and sometimes osmotic diuresis (like mannitol) to prevent severe nephrotoxicity.
Equipment Precaution: Do not use needles or administration sets containing aluminum components, as a chemical reaction will cause precipitation and loss of potency.
Side Effects & Precautions
Common Side Effects: Severe nausea, vomiting, alopecia, and mild bone marrow depression.
Serious Risks: Nephrotoxicity (cumulative renal impairment), ototoxicity (tinnitus, high-frequency hearing loss), and peripheral neurotoxicity.
Contraindications: Pre-existing renal impairment, myelosuppression, hearing impairment, and known hypersensitivity to platinum-containing compounds.
PRESCRIPTION MEDICINE IS : YES
Disclaimer : Cislieva 50 mg Injection is a prescription chemotherapy drug. It must be administered strictly under the supervision of a qualified oncologist or healthcare professional in a clinical setting. Ernest Oncology supplies this medication in compliance with all applicable international pharmaceutical export laws and regulations.
🌐 Websites:
📧 Email: exports@ernestpharmaceuticals.com
📦 Business Type: Exporter | Bulk Supplier | Distributor
📲 WhatsApp: +91 93599 02383
🔗 https://wa.me/919359902383
